A highly significant increase was observed in the serum level sTLR9 in non-metastatic (423.65 ± 114.55) and metastatic groups (493.62 ± 153.07) compared to healthy controls women (310.20 ± 52.57).
← all excerpts
Associations Between Serum Soluble Toll-like Receptors 4 and 9 and Breast Cancer in Egyptian Patients.
1
—
—